ArticleStroke (Hoboken, N.J.)2025
Endovascular Thrombectomy in Cancer-Related Stroke: Comparison of Thrombectomy Methods.
Article in Stroke (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal first-line device choice for endovascular treatment (EVT) of cancer-related stroke remains largely unknown. In this study, we evaluated the efficacy and safety of the EVT methods for treating cancer-related stroke thrombi.
methodsWe retrospectively analyzed 78 patients with cancer-related stroke who underwent EVT between February 2011 and July 2024. Patients were compared based on the first-line EVT technique (combined [
resultsThe primary efficacy did not differ between the first-line EVT techniques (first-pass effect: combined 34.5% versus SR only 17.1% versus CA 35.7%;
conclusionsIn EVT for cancer-related stroke, the dual-layered stent retriever device demonstrated superior efficacy in higher rates of first-pass effect without increasing the risk of symptomatic intracranial hemorrhage. These findings suggest that the dual-layered SR may be preferred as the first-line treatment option for EVT in cancer-related stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.